CTOs on the Move

Diagenode

www.diagenode.com

 
Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company`s latest innovations include a unique, full automation system, the industry`s most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.diagenode.com
  • 400 Morris Ave Ste 101
    Denville, NJ USA 07834
  • Phone: 862.209.4680

Executives

Name Title Contact Details

Similar Companies

Abbott Diabetes Care

Abbott Diabetes Care is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

M3 Biotechnology

M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.

SyntheZyme

SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how

ConjuGon Inc

ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconova

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.